5 Stocks Backed by High Efficiency for Solid Gains Amid Volatility
- Invest in stocks of AMRX, CRON, CSV, BFST and APH to tap their high-efficiency levels.
- 11/05/2024
|
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline
- Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/01/2024
|
How to Find Great Cheap Stocks Under $10 to Buy in October
- On top of their cheap price tags, Wall Street analysts are high on all of these stocks and their improving earnings outlooks earn them strong Zacks Ranks.
- 10/15/2024
|
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?
- Here is how Amneal Pharmaceuticals (AMRX) and Astrazeneca (AZN) have performed compared to their sector so far this year.
- 10/14/2024
|
Amneal to Report Third Quarter 2024 Results on November 8, 2024
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report Third Quarter 2024 Results on November 8, 2024.
- 10/08/2024
|
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
- BRIDGEWATER, N.J. & NEW YORK--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, and Metsera, Inc. (“Metsera”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that they have entered into a collaboration agreement to enable the efficient development and large-scale supply of a portfolio of new weight loss medicines globally. The col.
- 10/01/2024
|
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's Disease
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's Disease.
- 09/23/2024
|
Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates
- AMRX stock gains 29.3% in a month due to the FDA's approval of Parkinson's Disease drug, Crexont.
- 09/03/2024
|
Despite Fast-paced Momentum, Amneal (AMRX) Is Still a Bargain Stock
- If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
- 08/21/2024
|
5 Small Drug Stocks to Buy as Innovation Reaches Peak
- Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.
- 08/16/2024
|
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2024 Earnings Call Transcript
- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q2 2024 Earnings Conference Call August 9, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President & Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President & Chief Financial Officer Joe Renda - Senior Vice President & Chief Commercial Officer, Specialty Conference Call Participants David Amsellem - Piper Sandler Leszek Sulewski - Truist Securities Operator Good morning and welcome to the Amneal Pharmaceuticals Second Quarter 2024 Earnings Call. I'd now like to turn the call over to Amneal's Head of Investor Relations, Tony DiMeo.
- 08/09/2024
|
Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics
- While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 08/09/2024
|
AMNEAL PHARMACEUTICALS, INC. (AMRX) Soars to 52-Week High, Time to Cash Out?
- Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- 08/09/2024
|
Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates
- Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.19 per share a year ago.
- 08/09/2024
|
Wall Street's Insights Into Key Metrics Ahead of Amneal (AMRX) Q2 Earnings
- Get a deeper insight into the potential performance of Amneal (AMRX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
- 08/07/2024
|
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q2 Earnings Expected to Decline
- Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/02/2024
|
Amneal Pharmaceuticals (AMRX) is a Great Momentum Stock: Should You Buy?
- Does Amneal Pharmaceuticals (AMRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 07/29/2024
|
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
- Here is how Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
- 07/29/2024
|
Amneal (AMRX) Is Attractively Priced Despite Fast-paced Momentum
- Amneal (AMRX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
- 07/29/2024
|
Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success
- Amneal Pharmaceuticals has seen a significant increase in its share price of >400% after hitting an all-time low in March 2023. The company reported record revenues in Q1 2024, with growth in all three reportable segments - Generics, Specialty, and AvKare. Amneal is projecting new product launches and international expansion to add multi-billions of dollars of revenues by 2027, and profitability - on an adjusted basis at least - is in evidence.
- 07/10/2024
|
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced the launch of FOCINVEZ™, a ready-to-use injectable. Unlike other versions of fosaprepitant, this single-dose vial product is free of Polysorbate 80 and does not require reconstitution or dilution and can be administered directly from the vial using the included vial hanger. FOCINVEZ for injection is indicated in adults and pediatric patients 6 months of age and older, in c.
- 07/09/2024
|
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the continued expansion of its injectables portfolio with six new injectable product launches during the second quarter of 2024, bringing the Company's total number of commercial injectable products available for the U.S. institutional market to over 40. The growth of Amneal's broad injectables portfolio will help address shortages of critical products where there may be l.
- 06/05/2024
|
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California.
- 05/22/2024
|
Amneal to Participate at Upcoming Investor Conference
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conference.
- 05/22/2024
|
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2024 Earnings Call Transcript
- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q1 2024 Results Earnings Conference Call May 3, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President and Chief Financial Officer Joe Renda - Senior Vice President, Chief Commercial Officer, Specialty Conference Call Participants Nathan Rich - Goldman Sachs Leszek Sulewski - Truist Securities David Amsellem - Piper Sandler Balaji Prasad - Barclays Capital Chris Schott - J.P. Morgan Operator Good morning and welcome to Amneal Pharmaceuticals First Quarter 2024 Earnings Call.
- 05/03/2024
|
Drugmaker Amneal agrees to $270 million U.S. opioid settlement
- Amneal Pharmaceuticals said on Friday it had reached a deal valued at more than $270 million to resolve claims it helped fuel the deadly U.S. opioid epidemic, becoming the latest drug company to settle lawsuits over the addiction crisis brought by states and local governments.
- 05/03/2024
|
Amneal (AMRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
- Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 05/03/2024
|
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
- Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago.
- 05/03/2024
|
Amneal Reports First Quarter 2024 Financial Results
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--AMNEAL REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS.
- 05/03/2024
|
California teams with Amneal Pharma for cheaper, generic version of Narcan
- SACRAMENTO, Calif. — California will soon begin selling its own generic version of Narcan — the drug that can save someone's life during an opioid overdose — under a deal announced Monday by Democratic Gov.
- 04/29/2024
|
Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?
- Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 04/25/2024
|
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine.
- 04/16/2024
|
Amneal to Report First Quarter 2024 Results on May 3, 2024
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report First Quarter 2024 Results on May 3, 2024.
- 04/10/2024
|
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Ring the Nasdaq Closing Bell on April 2, 2024.
- 03/28/2024
|
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension.
- 03/25/2024
|
Amneal (AMRX) Stock Jumps 7.3%: Will It Continue to Soar?
- Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 03/20/2024
|
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript
- Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript
- 03/01/2024
|
Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say
- The headline numbers for Amneal (AMRX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 03/01/2024
|
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings Estimates
- Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.23 per share a year ago.
- 03/01/2024
|
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December 31, 2023. “Amneal had a very successful year in 2023 as we delivered strong execution and growth across our diversified pharmaceutical business. We are starting 2024 with substantial momentum and key catalysts, including complex high-value products, biosimilars and specialty, to further expand our reach. Again.
- 03/01/2024
|
Countdown to Amneal (AMRX) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
- Beyond analysts' top -and-bottom-line estimates for Amneal (AMRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
- 02/27/2024
|
Amneal (AMRX) Shows Fast-paced Momentum But Is Still a Bargain Stock
- If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
- 02/21/2024
|
Amneal to Participate at Upcoming Investor Conference
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer, will participate in the following investor conference. Barclays 26th Annual Global Healthcare Conference March 13, 2024 Miami, FL Fireside chat – 8:30 AM ET One-on-one meetings to follow A live webcast of the presentation will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. A replay of the we.
- 02/13/2024
|
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
- BRIDGEWATER, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has provided a Complete Response resubmission to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson's disease (PD).
- 02/08/2024
|
The Jobs Report Blows Away Forecasts
- January's payrolls report shows 353,000 jobs
- 02/02/2024
|
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its fourth quarter and full year 2023 financial results on Friday, March 1, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com.
- 01/31/2024
|
GSK, Amneal, Kaléo delist patents from FDA's orange book
- Pharmaceutical companies, GSK (GSK), Amneal Pharmaceuticals (AMRX) and Kaléo have agreed to delist some of their patents from the FDA's orange book. GSK withdrew four inhaler patents and Amneal withdrew epinephrine injection patents.
- 12/22/2023
|
Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company
- Amneal Pharmaceuticals' stock price has been on a strong bull run, now exceeding $5 per share and up over >145% this year. The company experienced losses in 2018 and 2019 but has since seen improvements in revenues and net income as the management team has been replaced. Amneal has made strategic acquisitions and has shown progress in its financials, leading to a positive outlook for 2024 and beyond.
- 12/09/2023
|
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2023 Earnings Call Transcript
- Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Anthony DiMeo - Head-Investor Relations Chirag Patel - Co-Founder & Co-Chief Executive Officer Chintu Patel - Co-Founder & Co-Chief Executive Officer Tasos Konidaris - Chief Financial Officer Joe Renda - Senior Vice President & Chief Commercial Officer-Specialty Harsher Singh - Senior Vice President-Biosciences Conference Call Participants Leszek Sulewski - Truist Balaji Prasad - Barclays Operator Good morning, and welcome to the Amneal Third Quarter 2013 Earnings Call. I will now turn the call over to Amneal Head of Investor Relations, Anthony DiMeo.
- 11/07/2023
|
Amneal (AMRX) Upgraded to Buy: Here's Why
- Amneal (AMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 10/25/2023
|
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
- Here is how Amneal Pharmaceuticals (AMRX) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.
- 10/25/2023
|
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
- Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/17/2023
|
Here Is Why Bargain Hunters Would Love Fast-paced Mover Amneal (AMRX)
- Amneal (AMRX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
- 10/06/2023
|
Penny Stocks To Buy? 5 To Watch With Big News This Week
- Investors often rely on stock market news to stay abreast of everything, ranging from low-cost penny stocks to industry giants such as Apple or Tesla. It's no secret that news can ignite excitement and skepticism in the blink of an eye, fueling speculation and thereby increasing market volatility.
- 08/07/2023
|
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Top Estimates
- Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.19 per share a year ago.
- 08/04/2023
|
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
- Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/21/2023
|
Why Shares of Amneal Pharmaceuticals Are Plunging Wednesday
- Amneal has more than 270 products. On Tuesday, the company launched a generic for Xyrem to treat excessive daytime sleepiness.
- 07/05/2023
|
Amneal (AMRX) Shares Down on CRL for Parkinson's Disease Drug
- Amneal (AMRX) suffers a setback as the FDA issues a complete response letter (CRL) to its new drug application (NDA) for IPX203 for treating Parkinson's disease.
- 07/05/2023
|
US FDA declines to approve Amneal Pharma's Parkinson's drug
- The U.S. Food and Drug Administration (FDA) has declined to approve Amneal Pharmaceuticals' drug for Parkinson's disease due to inadequate safety data on the treatment to help control symptoms in patients for a longer duration, the company said on Monday.
- 07/03/2023
|
Best Penny Stocks To Buy Now? 4 to Watch Under $5 This Week
- Penny stocks to watch under $5. The post Best Penny Stocks To Buy Now?
- 05/18/2023
|
3 Top Penny Stocks To Watch After Big News This Week
- Hot penny stocks with big news this week. The post 3 Top Penny Stocks To Watch After Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/16/2023
|
Amneal Pharmaceuticals' stock soars 14% premarket after company offers upbeat Q1 guidance
- Amneal Pharmaceuticals Inc.'s stock AMRX, -2.16% soared 14% in premarket trade Monday, after the generics and specialty pharmaceuticals company offered first-quarter guidance that topped consensus estimates. Bridgewater, N.J.
- 04/17/2023
|
Generic drugs are most likely to face shortages due to market failures in affordability
- CNBC's Meg Tirrell joins 'Closing Bell Overtime' to discuss growing pharmaceutical shortages, increasing debt hindering generic drug availability, and more.
- 03/29/2023
|
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates
- Amneal (AMRX) delivered earnings and revenue surprises of 9.52% and 4.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/02/2023
|
Best Penny Stocks To Buy? 4 Stocks Under $3 To Watch This Week
- Penny stocks under $3 to watch this week. The post Best Penny Stocks To Buy?
- 02/13/2023
|
Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years
- Intercept reached a settlement with Amneal that delays a generic version of its only product. In response, ICPT stock surged Wednesday.
- 01/25/2023
|
Amneal to Participate at Upcoming Investor Conferences
- BRIDGEWATER, N.J.--( BUSINESS WIRE )--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that the management team will attend the following investor conferences:
- 11/23/2022
|
FDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For Review
- Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.
- 11/14/2022
|
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2022 Earnings Call Transcript
- Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q3 2022 Earnings Conference Call November 4, 2022 8:30 AM ET Company Participants Chirag Patel - Co-Founder, Co-Chief Executive Officer Chintu Patel - Co-Founder and Co-Chief Executive Officer Anastasios Konidaris - Executive Vice President and Chief Financial Officer Harsher Singh - Senior Vice President, Biosciences Jason Daly - Senior Vice President and Chief Legal Officer Gustavo Pesquin - EVP, Specialty Conference Call Participants David Amsellem - Piper Sandler Michaela Diverio - Barclays Gary Nachman - BMO Capital Markets Nathan Rich - Goldman Sachs Elliot Wilbur - Raymond James Gregory Fraser - Truist Securities Operator Hello everyone and welcome to the Amneal Third Quarter 2022 Conference Call. My name is Emily and I will be your operator today.
- 11/04/2022
|
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Lag Estimates
- Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 3.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/04/2022
|
Amneal Pharmaceuticals, Inc. (AMRX) Management Team on Q2 2022 Results - Earnings Call Transcript
- Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q2 2022 Earnings Conference Call August 5, 2022 8:30 AM ET Company Participants Anthony DiMeo - Senior Director of Investor Relations Chirag Patel - Co-Founder, Co-Chief Executive Officer, President & Director Chintu Patel - Co-Founder & Co-Chief Executive Officer Anastasios Konidaris - Executive Vice President & Chief Financial Officer Harsher Singh - Head of Biosciences Jason Daly - Senior Vice President, Chief Legal Officer & Corporate Secretary Conference Call Participants Balaji Prasad - Barclays Nathan Rich - Goldman Sachs David Amsellem - Piper Sandler Gary Nachman - BMO Capital Markets Greg Fraser - Truist Securities Elliot Wilbur - Raymond James Ekaterina Knyazkova - JPMorgan Operator Hello and welcome to today's Amneal 2Q 2022 Earnings Conference Call. My name is Elliot and I will be coordinating your call today.
- 08/05/2022
|
Amneal Pharmaceuticals (AMRX) Lags Q2 Earnings Estimates
- Amneal (AMRX) delivered earnings and revenue surprises of -5% and 4.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2022
|
Amneal to Report Second Quarter 2022 Results on August 5, 2022
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2022 financial results on Friday August 5, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on August 5, 2022. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com
- 07/08/2022
|
Amneal Pharmaceuticals, Inc. (AMRX) Management Team on Q1 2022 Results - Earnings Call Transcript
- Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Tony DiMeo – Head-Investor Relations Chirag Patel – President and Co-Chief Executive Officer Chintu Patel – Co-Chief Executive Officer Tasos Konidaris – Chief Financial Officer Andy Boyer – Executive Vice President and Chief Commercial Officer-Generics Conference Call Participants Mikaela Franceschina – Barclays David Amsellem – Piper Sandler Gary Nachman – BMO Capital Markets Operator Hello and welcome to Amneal's First Quarter 2022 Conference Call. My name is Alex and I will be coordinating the call today.
- 05/04/2022
|
Amneal Pharmaceuticals (AMRX) Q1 Earnings Meet Estimates
- Amneal (AMRX) delivered earnings and revenue surprises of 0% and 0.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/04/2022
|
Amneal Pharmaceuticals: Generics And Biosimilars Play Has Strong Upside Potential Under New / Old Management
- Amneal Pharmaceuticals shares have fallen in value from $24 to $4 since September 2018.
- 03/30/2022
|
Amneal Pharmaceuticals (AMRX) CEO, Chirag Patel on Q4 2021 Results - Earnings Call Transcript
- Amneal Pharmaceuticals (AMRX) CEO, Chirag Patel on Q4 2021 Results - Earnings Call Transcript
- 03/02/2022
|
Amneal Pharmaceuticals (AMRX) Lags Q4 Earnings Estimates
- Amneal (AMRX) delivered earnings and revenue surprises of -5.26% and 1.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/02/2022
|
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
- Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/23/2022
|
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
- Here is how Amneal Pharmaceuticals (AMRX) and Athersys, Inc. (ATHX) have performed compared to their sector so far this year.
- 02/04/2022
|
Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced today that the Company will release its fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2022. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website
- 02/04/2022
|
Is Amneal Pharmaceuticals (AMRX) a Suitable Pick for Value Investors?
- Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.
- 01/28/2022
|
Amneal's $83M Saol Acquisition Deal Expands Its Neurology Presence Into Spasticity
- Amneal Pharmaceuticals Inc (NYSE: AMRX) has agreed to acquire Saol's Baclofen franchise, including Lioresal, Lyvispah, and a pipeline product under development for $83.5 million in cash. The acquisition expands Amneal's commercial institutional and specialty portfolio in neurology while adding commercial infrastructure in advance of its entry into the biosimilar institutional market.
- 01/05/2022
|
Penny Stocks To Buy Now According To Insiders In December 2021
- Insiders are buying these penny stocks during "tax loss season" The post Penny Stocks To Buy Now According To Insiders In December 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/20/2021
|
TherapeuticsMD, Amneal Settle US Patent Litigation For Bijuva
- TherapeuticsMD Inc (NASDAQ: TXMD) has settled the previously disclosed U.S. patent litigation for Bijuva with Amneal Pharmaceuticals Inc (NYSE: AMRX). Bijuva is a prescription medicine used to treat vasomotor symptoms (hot flashes) related to menopause.
- 12/08/2021
|
Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q3 2021 Results - Earnings Call Transcript
- Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q3 2021 Results - Earnings Call Transcript
- 11/03/2021
|
Amneal Posts Mixed Bag Q3 Earnings; Acquires Puniska To Bolster Injectable Business
- Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q3 revenue of $529 million, a marginal increase of 2% Y/Y, missing the consensus of $545.06 million. The increase was driven by Generic product launches and growth in Specialty products Rytary and Unithroid, partially offset by price erosion in its base business and slow demand at the start of the flu season.
- 11/03/2021
|
Amneal Pharmaceuticals (AMRX) Tops Q3 Earnings Estimates
- Amneal (AMRX) delivered earnings and revenue surprises of 5.00% and -3.27%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2021
|
Amneal Pharmaceuticals (AMRX) to Report Q3 Results: Wall Street Expects Earnings Growth
- Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/29/2021
|
Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study
- Amneal's (AMRX) IPX-203 increases "Good On" time by 1.55 hours per dose versus immediate-release CD/LD in patients with Parkinson's disease.
- 08/26/2021
|
AMRX Stock: Over 10% Increase Pre-Market Explanation
- The stock price of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) increased by over 10% pre-market. This is why it happened.
- 08/26/2021
|
Amneal's Parkinson's Candidate Shows Efficacy In Pivotal Trial
- Amneal Pharmaceuticals Inc (NYSE: AMRX) announced topline data from the Phase 3 RISE-PD trial evaluating IPX-203 in patients with Parkinson's disease who have motor fluctuations. Amneal plans to submit a marketing application for IPX-203 with the FDA in mid-2022.
- 08/26/2021
|
Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q2 2021 Results - Earnings Call Transcript
- Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q2 2021 Results - Earnings Call Transcript
- 08/09/2021
|
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Top Estimates
- Amneal (AMRX) delivered earnings and revenue surprises of 38.89% and 1.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2021
|
Amneal Q2 Earnings Tops Estimates; Backs FY21 Guidance
- Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q2 revenue of $535 million, an increase of 15% Y/Y, beating the consensus of $523.25 million. Sales growth was driven by Generic product launches, specialty products Rytary & Unithroid, and overall volume growth within Generics and AvKARE segments.
- 08/09/2021
|
Amneal Pharmaceuticals: Q2 Earnings Insights
- Shares of Amneal Pharmaceuticals (NYSE:AMRX) moved higher by 0.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 92.31% year over year to $0.25, which beat the estimate of $0.19.
- 08/09/2021
|
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/02/2021
|
AMRX Stock Increased 8.8%: Why It Happened
- The stock price of Amneal Pharmaceuticals Inc (NYSE: AMRX) increased 8.8% today. This is why it happened.
- 07/20/2021
|
Amneal Receives Approval for Generic TobraDex®
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio. Dexamethasone and Tobramycin Ophthalmic Suspension 0.3%/0.1% is the generic version of TobraDex®, which is indicated for steroid-responsive inflamm
- 07/19/2021
|
10 Stocks Under $10 to Buy In July for the Rest of the Year
- 10 Stocks to watch now trading under $10 with significant upside potential The post 10 Stocks Under $10 to Buy In July for the Rest of the Year appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn't matter if you have $500 in savings or $5 million.
- 07/13/2021
|
AMRX vs. ZTS: Which Stock Should Value Investors Buy Now?
- AMRX vs. ZTS: Which Stock Is the Better Value Option?
- 07/07/2021
|
10 Cheap Stocks Under $10 the Pros Are Buying
- If you're looking for a cheap stock to buy, check out this list of 10 highly rated picks that are priced under $10.
- 05/21/2021
|
Amneal to Virtually Participate at Upcoming Investor Conferences
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its management team will virtually attend the following investor conferences: RBC Global Healthcare Conference May 18, 2021 Fireside Chat – 1:55 p.m. Eastern Time Goldman Sachs 42nd Annual Global Healthcare Conference June 10, 2021 Fireside Chat – 3:50 p.m. Eastern Time A live webcast of the presentations will be accessible through the Investor Relations section of the Company's we
- 05/14/2021
|
AMRX or ZTS: Which Is the Better Value Stock Right Now?
- AMRX vs. ZTS: Which Stock Is the Better Value Option?
- 05/10/2021
|
Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q1 2021 Results - Earnings Call Transcript
- Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q1 2021 Results - Earnings Call Transcript
- 05/07/2021
|
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates
- Amneal (AMRX) delivered earnings and revenue surprises of 11.11% and -2.81%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/07/2021
|
Amneal Reports First Quarter 2021 Financial Results
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the first quarter ended March 31, 2021. “Amneal delivered solid first quarter results, continuing our positive momentum as we consistently execute against our Amneal 2.0 strategic vision of long-term sustainable growth,” said Chirag and Chintu Patel, Co-Chief Executive Officers. “Our strong profitability reflects the validity of our strategy, our diversified and relevant
- 05/07/2021
|
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Amneal Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
- NEW YORK, April 12, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Amneal Pharmaceuticals, Inc. (NYSE: AMRX). If you are a shareholder of Amneal Pharmaceuticals, Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: http://pjlfirm.com/amneal-pharmaceuticals-inc/ You may also contact Robert H.
- 04/12/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Amneal Pharmaceuticals, Inc. (AMRX)
- New York, New York--(Newsfile Corp. - March 31, 2021) - Levi & Korsinsky announces it has commenced an investigation of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/amneal-pharmaceuticals-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.
- 03/31/2021
|
A Trio of Small Caps for the Growth-Oriented Investor
- Investors who chase growth could be interested in the following small-cap stocks as they represent companies whose trailing 12-month net earnings per share improved significantly on a year-over-year basis.
- 03/31/2021
|
Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q4 2020 Results - Earnings Call Transcript
- Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q4 2020 Results - Earnings Call Transcript
- 02/26/2021
|
Amneal Pharmaceuticals (AMRX) Surpasses Q4 Earnings and Revenue Estimates
- Amneal (AMRX) delivered earnings and revenue surprises of 7.69% and 1.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/26/2021
|
Amneal Receives Approval for Generic Version of Ortho Evra®
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for 150 mcg/day Norelgestromin and 35 mcg/day Ethinyl Estradiol Transdermal System. In conjunction with its approval, Amneal received a Competitive Generic Therapy (CGT) designation by the FDA and has been granted 180 days of exclusivity. Amneal's Norelgestr
- 02/26/2021
|
Amneal Reports Fourth Quarter and Full Year 2020 Financial Results
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the fourth quarter and full year ended December 31, 2020. "We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal," said Chirag and Chintu Patel, Co-Chief Executive Officers. "In just a year and a half, we have made significant strides towards strategically positioning Amneal, both operationally and financially, for the next p
- 02/26/2021
|
Why Amneal Pharmaceuticals (AMRX) Might Surprise This Earnings Season
- Amneal Pharmaceuticals (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/25/2021
|
AMRX or CORT: Which Is the Better Value Stock Right Now?
- AMRX vs. CORT: Which Stock Is the Better Value Option?
- 02/10/2021
|
Amneal to Report Fourth Quarter & Full Year 2020 Results on February 26, 2021
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2020 financial results on Friday, February 26, 2021, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on February 26, 2021. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https:/
- 02/04/2021
|
AMRX or PCRX: Which Is the Better Value Stock Right Now?
- AMRX vs. PCRX: Which Stock Is the Better Value Option?
- 01/15/2021
|
Amneal to Acquire Substantially All of Kashiv Specialty Pharmaceuticals
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (the “Company”) (NYSE:AMRX) and Kashiv BioSciences LLC (“Kashiv”) today announced they have entered into a definitive agreement under which Amneal Pharmaceuticals LLC (“Amneal”), a wholly-owned subsidiary of the Company, will acquire a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (“Kashiv Specialty”), a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and
- 01/12/2021
|
Amneal to Virtually Participate at the 39th Annual J.P. Morgan Healthcare Conference
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Amneal's Co-Chief Executive Officer and President, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021 at 2:50 PM Eastern Time. A live webcast of the presentation will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. A replay of the webcast will be posted shortly after the
- 01/05/2021
|
Amneal Analyst: Pharma Well-Positioned Ahead Of 2021 Generic Launches
- As part of its outlook for biopharma companies in 2021, Guggenheim Securities turned bullish on Amneal Pharmaceuticals Inc (NYSE: AMRX). The Amneal Analyst: Dana Flanders upgraded Amneal from Neutral to Buy with a $5.50 price target.
- 12/14/2020
|
Amneal Receives Abbreviated New Drug Application Approval for Acyclovir Cream, 5%
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) today announced that it has received approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Acyclovir Cream, 5%. Acyclovir Cream, 5%, is the generic version of Zovirax® for treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older. The product is available by prescription only and is associat
- 11/11/2020
|
Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q3 2020 Results - Earnings Call Transcript
- Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q3 2020 Results - Earnings Call Transcript
- 11/06/2020
|
Recap: Amneal Pharmaceuticals Q3 Earnings
- Shares of Amneal Pharmaceuticals (NYSE:AMRX) rose 1.0% in pre-market trading after the company reported Q3 results.
- 11/06/2020
|
Amneal Reports Third Quarter 2020 Financial Results
- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the third quarter ended September 30, 2020. “Amneal delivered another strong quarter, providing further evidence that our Amneal 2.0 strategy is positioning the company for sustained growth,” said Chirag and Chintu Patel, Co-Chief Executive Officers. “While the COVID pandemic continues to affect some aspects of the business, we continue to focus on execution, improving t
- 11/06/2020
|
Epinephrine Autoinjector Market Highlights the Impact of COVID-19 2020-2024 | Increasing Prevalence of Allergies to boost Market Growth | Technavio
- The Global Epinephrine Autoinjector Market will grow by USD 762.51 mn during 2020-2024
- 08/07/2020
|
Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates
- Amneal (AMRX) delivered earnings and revenue surprises of 30.00% and 3.73%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/06/2020
|
Amneal Reports Second Quarter 2020 Financial Results
- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the second quarter ended June 30, 2020.
- 08/06/2020
|
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
ABIOMED, Inc. (NASDAQ: ABMD)
Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (announced a U.S. government grant for a...
- 08/06/2020
|
Amneal (AMRX) to Report Q2 Earnings: What's in the Cards?
- Amneal (AMRX) will provide financial updates when it reports second-quarter 2020 results.
- 08/03/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
Amneal Pharmaceuticals (AMRX) Stock Sinks As Market Gains: What You Should Know
- Amneal Pharmaceuticals (AMRX) closed the most recent trading day at $4.33, moving -0.69% from the previous trading session.
- 07/31/2020
|
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/30/2020
|
Kodak’s stock triples as company announces pandemic plan to start making pharmaceutical ingredients
- The Trump administration’s $765 million loan to the Eastman Kodak Co. to launch a business making pharmaceutical ingredients sent shares of the once iconic...
- 07/29/2020
|
Amneal Pharmaceuticals (AMRX) Gains As Market Dips: What You Should Know
- In the latest trading session, Amneal Pharmaceuticals (AMRX) closed at $4.46, marking a +0.45% move from the previous day.
- 07/23/2020
|
Can Amneal (AMRX) Keep the Earnings Surprise Streak Alive?
- Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/22/2020
|
Amneal Pharmaceuticals (AMRX) Gains But Lags Market: What You Should Know
- Amneal Pharmaceuticals (AMRX) closed the most recent trading day at $4.86, moving +0.21% from the previous trading session.
- 07/17/2020
|
Could The Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Ownership Structure Tell Us Something Useful?
- The big shareholder groups in Amneal Pharmaceuticals, Inc. (NYSE:AMRX) have power over the company. Insiders often own...
- 07/16/2020
|
DBV Technologies' Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
- DBVT reports positive extension study data. Amneal receives FDA approval for Generic Fluphenazine Hydrochloride.
- 07/13/2020
|
Company News for Jul 13, 2020
- Companies in the news are: BNGO, AMRX, ALT, EXPR
- 07/13/2020
|
Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer
- FLORHAM PARK, N.J., July 13, 2020 -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing.
- 07/13/2020
|
Lannett to cut jobs following FDA approval of competing generic drug
- Shares of Lannett Company Inc. undefined gained 0.2% after the company said it will cut 80 positions, about 8.5% of its total workforce, over concerns that...
- 07/13/2020
|
Lannett to cut jobs following FDA approval of competing generic drug
- Shares of Lannett Company Inc. gained 0.2% after the company said it will cut 80 positions, about 8.5% of its total workforce, over concerns that its generic fluphenazine product will face competition from Amneal Pharmaceuticals Inc. , which last week received a Food and Drug Administration approval for a generic form of the antipsychotic. Amneal said last week that annual U.S. sales of fluphenazine in the U.S. are $143 million. "LCI's dominance of the generic fluphenazine market, a key high margin driver and LCI's largest product in the wake of the loss of levothyroxine, ended yesterday with Amneal's entrance," Raymond James analyst Elliot Wilbur told investors on Friday. "Though competition was 'expected,' it is always hoped to happen later rather than sooner." The job losses will be at Lannett's Seymour, Indiana plant. Consolidating research & development in one location in Philadelphia is expected to save the company $15 million annually. Lannett's stock is down 34.9% year-to-date, while the S&P; 500 has declined 1.4%.
- 07/13/2020
|
Amneal Launches Generic Fluphenazine Following ANDA Approval by FDA
- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg. Fluphenazine Hydrochloride is the generic version of Prolixin for treatment of schizophrenia. Amneal immediately initiated commercialization activities across all dosages.
- 07/10/2020
|
Amneal Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
- Amneal Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
- 07/09/2020
|
Amneal Pharmaceuticals (AMRX) Stock Sinks As Market Gains: What You Should Know
- Amneal Pharmaceuticals (AMRX) closed the most recent trading day at $4.51, moving -0.66% from the previous trading session.
- 07/08/2020
|
Amneal to Report Second Quarter 2020 Results on August 6, 2020
- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2020 financial results on Thursday, August 6, 2020, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on August 6, 2020.
- 07/08/2020
|
Amneal to Report Second Quarter 2020 Results on August 6, 2020
- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2020 financial results on Thursday, August
- 07/08/2020
|
AMRX vs. COLL: Which Stock Should Value Investors Buy Now?
- AMRX vs. COLL: Which Stock Is the Better Value Option?
- 07/07/2020
|
Parametric Portfolio Associates LLC Grows Stock Position in Amneal Pharmaceuticals Inc (NYSE:AMRX)
- Parametric Portfolio Associates LLC grew its position in Amneal Pharmaceuticals Inc (NYSE:AMRX) by 17.1% during the 1st quarter, HoldingsChannel.com reports. The fund owned 236,760 shares of the company’s stock after buying an additional 34,611 shares during the quarter. Parametric Portfolio Associates LLC’s holdings in Amneal Pharmaceuticals were worth $824,000 at the end of the most […]
- 07/05/2020
|
51,034 Shares in Amneal Pharmaceuticals Inc (NYSE:AMRX) Acquired by Voloridge Investment Management LLC
- Voloridge Investment Management LLC bought a new position in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 51,034 shares of the company’s stock, valued at approximately $178,000. Other hedge funds have also bought and sold shares of the company. […]
- 07/04/2020
|
Alliancebernstein L.P. Sells 19,700 Shares of Amneal Pharmaceuticals Inc (NYSE:AMRX)
- Alliancebernstein L.P. reduced its stake in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 8.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 213,549 shares of the company’s stock after selling 19,700 shares during the quarter. Alliancebernstein L.P. owned about 0.07% of Amneal Pharmaceuticals […]
- 07/04/2020
|
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Pfizer (NYSE: PFE) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX
- 07/02/2020
|
How R&D Expenses Can Help You Pick Outperforming Stocks
- A simple two-rule screen can help you pick R&D-intensive stocks primed to outperform. The differences between R&D expenditures and capital expenditures vary bet
- 07/02/2020
|
CytoDyn Signs MOU With NIH of Mexico for Coronavirus Study
- CytoDyn's (CYDY) shares rise more than 20% as it inks an MOU with NIH of Mexico to conduct a COVID-19 study on leronlimab.
- 06/30/2020
|
Zogenix Gets FDA Nod for Dravet Syndrome Seizure Treatment
- Zogenix (ZGNX) gets FDA nod for Fintepla oral solution, CIV for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age or older.
- 06/26/2020
|
Balyasny Asset Management LLC Purchases Shares of 24,151 Amneal Pharmaceuticals Inc (NYSE:AMRX)
- Balyasny Asset Management LLC purchased a new stake in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 24,151 shares of the company’s stock, valued at approximately $84,000. A number of other institutional investors also recently modified […]
- 06/26/2020
|
AMRX vs. COLL: Which Stock Should Value Investors Buy Now?
- AMRX vs. COLL: Which Stock Is the Better Value Option?
- 06/19/2020
|
Jazz Pharmaceuticals (JAZZ) in Focus: Stock Moves 5.6% Higher
- Jazz Pharmaceuticals (JAZZ) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- 06/16/2020
|
IN BRIEF: Supreme Court will not hear generic drug price fixing discovery dispute
- The U.S. Supreme Court on Monday declined to hear generic drugmakers' challenge to a court order requiring them to turn over millions of pages of records to states and drug purchasers accusing them of fixing prices.
- 06/15/2020
|
Amneal Pharmaceuticals (AMRX): Hedge Funds Never Been Less Bullish
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
- 06/15/2020
|
Alprazolam Market 2020-2024 | Increasing Prevalence of Anxiety Disorders to Boost Growth | Technavio
- The Global Alprazolam Market will grow by USD 90.33 mn during 2020-2024
- 06/13/2020
|
Moving Average Crossover Alert: Amneal Pharmaceuticals
- Amneal Pharmaceuticals, Inc. (AMRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- 06/12/2020
|
Drug Makers Conspired To Fix Prices: CT Attorney General
- Drug Makers Conspired To Fix Prices: CT AG - Across Connecticut, CT - Connecticut Attorney General William Tong led 51 states and territories in filing a suit alleging price manipulation of generic drugs.
- 06/11/2020
|
COVID-19 Impact and Recovery Analysis- Active Pharmaceutical Ingredients Market 2020-2024 | Increasing Number of Type II DMFs to Boost Growth | Technavio
- The Global Active Pharmaceutical Ingredients Market will grow by USD 60.56 bn during 2020-2024
- 06/11/2020
|
Actinium Pharmaceuticals (ATNM) Jumps: Stock Rises 6.7%
- Actinium Pharmaceuticals (ATNM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- 06/09/2020
|
CAFC Says District Court Abused Its Discretion in Granting Attorney’s Fees
- The U.S. Court of Appeals for the Federal Circuit today reversed a district court decision awarding attorney’s fees to Luv n’ Care Ltd. (LNC) against Munchkin, Inc.
- 06/08/2020
|
Amneal's Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Amneal Pharmaceuticals.
- 06/08/2020
|
Federal Circuit Denies Attorney Fees for Work Done Before the USPTO
- On June 4, the U.S. Court of Appeals for the Federal Circuit (CAFC) denied a request by Almirall for attorney fees incurred for work on an inter partes review (IPR) and for work done in connection with a motion before the Federal Circuit in Amneal Pharmaceuticals v. Almirall.
- 06/08/2020
|
Trump Donor Sued the VA—Now He’s Getting Its COVID-19 Contracts
- The VA has inked 21 deals with Tennessee entrepreneur Troy Mizell’s AVMedical to supply everything from masks to thermometers to blood gas analyzers.
- 06/06/2020
|
Diabetes Medication Recall 2020: More Metformin Recalled For Cancer Fears
- More diabetes medication has been recalled for a possible cancer-causing ingredient. Here's what you need to know about the recall.
- 06/05/2020
|
Other Barks & Bites for Friday, June 5: China Gains on U.S. in Important Tech Sectors, DMCA Modernization Hearings and Copyright Office Studies State Sovereign Immunity Issues
- This week in Other Barks & Bites: a study from Bertelsmann Stiftung shows that China has made great strides in obtaining patents for important tech sectors; the Federal Circuit rules that attorney’s fees awards under Section 285 are not available for PTAB trials; and more.
- 06/05/2020
|
AMRX or COLL: Which Is the Better Value Stock Right Now?
- AMRX vs. COLL: Which Stock Is the Better Value Option?
- 06/03/2020
|
Diabetes Drug Recall 2020: Another Metformin Medication Recalled Over Cancer Concerns
- Another recall has been issued for the diabetes drug Metformin because it may contain a cancer-causing ingredient over the acceptable levels.
- 06/02/2020
|
New Strong Buy Stocks For May 26th
- New Strong Buy Stocks For May 26th
- 05/26/2020
|
The Independent Director of Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Jeffrey George, Just Bought A Few More Shares
- Even if it's not a huge purchase, we think it was good to see that Jeffrey George, the Independent Director of Amneal...
- 05/17/2020
|
Amneal (AMRX) Moves to Buy: Rationale Behind the Upgrade
- Amneal (AMRX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 05/15/2020
|
Amneal's Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Amneal Pharmaceuticals.
- 05/15/2020
|
Company News for May 12, 2020
- Companies In The News Are:
- 05/12/2020
|
Does Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Have A Particularly Volatile Share Price?
- If you're interested in Amneal Pharmaceuticals, Inc. (NYSE:AMRX), then you might want to consider its beta (a measure...
- 05/12/2020
|
U.S. RESEARCH ROUNDUP-Digital Realty Trust, Pilgrims Pride, Terraform Power
- Wall Street securities analysts revised their ratings and price targets on
several U.S.-listed companies, including Digital Realty Trust, Pilgrims Pride and Terraform Power,
on Tuesday.
HIGHLIGHTS
* Digital Realty Trust Inc : Citigroup cuts neutral from buy
* Pilgrims Pride Corp : Stephens raises to overweight from equal-weight
* Terraform Power Inc : RBC raises target price to $19 from $16
* Zimmer Biomet Holdings Inc : SunTrust Robinson raises TP to $132 from $125
Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday. Stock
entries are in alphabetical order.
* Acceleron pharma Inc : Cowen and Company raises price target to $121 from $109
* Albemarle Corp : Citigroup raises price target to $59 from $49
* Alphabet Inc : Citigroup raises price target to $1600 from $1400
* Amag Pharmaceuticals Inc : Cowen and Company cuts price target to $5 from $9
* AMN Healthcare Services Inc : Credit Suisse cuts target price to $62 from $81
* Amneal Pharmaceuticals Inc : SVB Leerink raises target price to $4 from $3
* Arbor Realty Trust Inc : KBW raises target price to $8 from $6
* Arch Capital Group Ltd : KBW cuts target price to $36 from $39
* Autonation Inc : JP Morgan raises target price to $40 from $37
* Avaya Holdings Corp : Citigroup raises price target to $13 from $8
* Bancorp Inc : Piper Sandler cuts target price to $11 from $12
* Bloom Energy Corp : Cowen and Company raises price target to $8 from $6
* Bluebird Bio Inc : Piper Sandler cuts target price to $70 from $75
* Bluebird Bio Inc : SVB Leerink raises target price to $137 from $135
* Cable One Inc : Keybanc raises target price to $2,105 from $1,968
* Caesars Entertainment Corp : Jefferies raises target price to $10 from $7
* Cardinal Health Inc : Mizuho raises target price to $56 from $50
* Ceridian Hcm Holding Inc : Citigroup raises price target to $77 from $64
* Ceva Inc : Cowen and Company raises price target to $40 from $37
* Choice Hotels International Inc : Jefferies raises target price to $70 from $60
* Choice Hotels International Inc : JP Morgan cuts target price to $59 from $85
* Choice Hotels International Inc : SunTrust Robinson raises TP to $67 from $66
* Cleveland-Cliffs Inc : Citigroup raises price target to $5 from $3.5
* CNA Financial Corp : KBW cuts target price to $35 from $36
* Continental Resources Inc : Susquehanna raises target price to $12 from $10
* Cornerstone Ondemand Inc : D.A. Davidson cuts target price to $40 from $64
* Cornerstone Ondemand Inc : RBC raises target price to $37 from $33
* Crinetics Pharmaceuticals Inc : SVB Leerink cuts target price to $39 from $43
* Cushman & Wakefield Plc : Citigroup cuts price target to $12 from $21
* Cytokinetics Inc : Needham raises price target to $34 from $24
* Cytokinetics Inc : Piper Sandler raises target price to $28 from $22
* Datadog Inc : Credit Suisse raises target price to $55 from $45
* Datadog Inc : Jefferies raises target price to $59 from $39
* Datadog Inc : JP Morgan raises target price to $65 from $60
* DCP Midstream LP : Credit Suisse raises target price to $9 from $7
* Dicerna Pharmaceuticals Inc : Citigroup cuts price target to $32 from $35
* Digital Realty Trust Inc : Citigroup cuts neutral from buy
* Digital Realty Trust Inc : Citigroup raises price target to $150 from $140
* Eagle Pharmaceuticals Inc : Piper Sandler raises target price to $50 from $47
* eBay Inc : CFRA cuts to sell from hold; cuts target price by $2 to $35
* Eldorado Resorts Inc : Jefferies raises target price to $38 from $29
* Eloxx Pharmaceuticals Inc : Canaccord Genuity cuts target price to $6 from $17
* Evelo Biosciences Inc : Jefferies cuts target price to $6 from $18
* Evolus Inc : SunTrust Robinson cuts target price to $12 from $18
* Fate Therapeutics Inc : Jefferies raises target price to $37 from $36
* First Guaranty Bancshares Inc : Piper Sandler cuts target price to $14 from $22
* Genpact Ltd : Cowen and Company raises target price to $41 from $39
* Golub Capital BDC Inc : KBW cuts target price to $13.5 from $16
* Green Dot Corp : BTIG raises target price to $40 from $35
* Green Dot Corp : Jefferies raises target price to $32 from $27
* Grocery Outlet Holding Corp : Jefferies raises target price to $52 from $51
* IAC/InterActiveCorp : Citigroup raises price target to $285 from $240
* Ii-Vi Inc : D.A. Davidson raises target price to $45 from $40
* Ii-Vi Inc : Piper Sandler raises target price to $54 from $40
* Intercept Pharmaceuticals Inc : Raymond James cuts target price to $145 from $148
* Intersect Ent Inc : Piper Sandler cuts target price to $14 from $23
* Kvh Industries Inc : Raymond James cuts target price to $10 from $12
* Linde Plc : Citigroup raises price target to $216 from $209
* Livent Corp : Credit Suisse cuts target price to $5 from $6
* Macrogenics Inc : Credit Suisse raises target price to $30 from $13
* Magellan Health Inc : Jefferies raises target price to $85 from $81
* Marriott : JP Morgan cuts target price to $88 from $129
* Mustang Bio Inc : Oppenheimer cuts target price to $13 from $15
* Myokardia Inc : Citigroup raises price target to $125 from $87
* Myokardia Inc : Wedbush raises target price to $127 from $90
* ON Semiconductor Corp : Needham raises price target to $20 from $17
* Park Hotels & Resorts Inc : Jefferies cuts target price to $9 from $10
* Paycom Software Inc : Citigroup raises price target to $315 from $262
* Paylocity Holding Corp : Citigroup raises price target to $124 from $94
* Pennymac Mortgage Investment Trust : KBW raises target price to $11.5 from $10
* Pilgrims Pride Corp : Stephens raises to overweight from equal-weight
* Pilgrims Pride Corp : Stephens raises target price to $28 from $20
* PRA Group Inc : KBW raises target price to $42 from $35
* Purple Innovation Inc : Keybanc raises target price to $16 from $12
* Purple Innovation Inc : Raymond James raises target price to $16 from $10
* Rattler Midstream LP : Simmons Energy raises target price to $8 from $5
* Ready Capital Corp : Piper Sandler raises target price to $10 from $8
* Scientific Games Corp : JP Morgan cuts target price to $11 from $25
* Seaworld Entertainment Inc : Keybanc raises target price to $19 from $17
* Select Energy Services Inc : Citigroup raises price target to $5.5 from $3
* SS&C Technologies Holdings Inc : Citigroup raises price target to $67 from $50
* Synchronoss Technologies : Canaccord Genuity cuts target price to $10 from $13
* Targa Resources Corp : Simmons Energy raises target price to $13 from $8
* Tenet Healthcare Corp : Raymond James cuts target price to $40 from $48
* Terraform Power Inc : RBC raises target price to $19 from $16
* Terreno Realty Corp : Stifel cuts target price to $56 from $60
* Tilray Inc : Cowen and Company cuts target price to $9 from $15
* T-Mobile US Inc : Citigroup raises price target to $115 from $103
* Trade Desk Inc : Citigroup raises price target to $320 from $240
* Under Armour Inc : JP Morgan cuts target price to $8 from $9
* Under Armour Inc : Keybanc cuts target price to $16 from $23
* Under Armour Inc : Piper Sandler cuts target price to $10 from $11
* Under Armour Inc : Susquehanna cuts target price to $4 from $6
* Under Armour Inc : Telsey Advisory Group cuts target price to $8 from $9
* Under Armour Inc : Wedbush cuts target price to $10 from $11
* Western Midstream Partners LP : Citigroup cuts price target to $7 from $23
* Williams Companies Inc : Credit Suisse cuts to neutral from outperform
* Xenia Hotels & Resorts Inc : Jefferies cuts target price to $8.50 from $11
* Zillow Group Inc : Stephens raises target price to $68 from $48
* Zimmer Biomet Holdings Inc : Canaccord Genuity raises TP to $137 from $135
* Zimmer Biomet Holdings Inc : Citigroup raises price target to $140 from $125
* Zimmer Biomet Holdings Inc : Needham cuts target price to $148 from $153
* Zimmer Biomet Holdings Inc : Piper Sandler cuts target price to $160 from $175
* Zimmer Biomet Holdings Inc : SunTrust Robinson raises TP to $132 from $125
(Compiled by Bengaluru Newsroom)
- 05/12/2020
|
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2020 Earnings Call Transcript
- Image source: The Motley Fool. Amneal Pharmaceuticals, Inc. (NYSE: AMRX)Q1 2020 Earnings CallMay 11, 2020, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning and welcome to the Amneal Pharmaceuticals First Quarter 2020 Earnings Conference Call.
- 05/12/2020
|
6 Stock Charts To Watch: AMRS, CYTK, DRNA, LX, MRNA, VAPO
- Stocks Analysis by Harry Boxer covering: SPDR S&P 500, Amyris Inc, BioCryst Pharmaceuticals Inc, Cytokinetics Inc. Read Harry Boxer's latest article on Investing.com
- 05/12/2020
|
Amneal Pharmaceuticals Inc. (AMRX) CEO Chirag Patel on Q1 2020 Results - Earnings Call Transcript
- Amneal Pharmaceuticals Inc. (NYSE:AMRX) Q1 2020 Earnings Conference Call May 11, 2020 08:30 AM ET Company Participants Tasos Konidaris - SVP and CFO Chirag Pate
- 05/11/2020
|
Amneal Pharmaceuticals (AMRX) Surpasses Q1 Earnings and Revenue Estimates
- Amneal (AMRX) delivered earnings and revenue surprises of 150.00% and 12.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/11/2020
|
Amneal Pharmaceuticals: Q1 Earnings Insights
- Shares of Amneal Pharmaceuticals (NYSE:AMRX) moved higher by 13% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 42.86% year over year to $0.20, which beat the estimate of $0.09.Revenue of $498,533,000 rose by 11.75% from the same period last year, which beat the estimate of $444,230,000.Looking Ahead Amneal Pharmaceuticals hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 11, 2020View more earnings on AMRXTime: 08:00 PM ETWebcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer;=https%3A%2F%2Finvestors.amneal.com%2Fevents-and-presentations%2Fdefault.aspx&eventid;=2160261&sessionid;=1&key;=E914BD59C23EF549366ECD92AF31432F®Tag;=&sourcepage;=registerPrice Action Company's 52-week high was at $13.66Company's 52-week low was at $2.27Price action over last quarter: Up 7.39%Company Overview Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products and Specialty products. Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. It generates a majority of its revenue from the Generic business segment.See more from Benzinga * 15 Healthcare Stocks Moving In Monday's Pre-Market Session * 18 Healthcare Stocks Moving In Monday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/11/2020
|
Amneal Reports First Quarter 2020 Financial Results
- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the first quarter ended March 31, 2020.
- 05/11/2020
|
Amneal Reports First Quarter 2020 Financial Results
- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the first quarter ended March 31, 2020. “We are proud of how
- 05/11/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
Is a Surprise Coming for Amneal (AMRX) This Earnings Season?
- Amneal (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/08/2020
|
COVID-19 Impact and Recovery Analysis- Epinephrine Autoinjector Market 2020-2024 | Increasing Prevalence of Allergies to Boost Growth | Technavio
- The epinephrine autoinjector market is poised to grow by 762.51 mn during 2020-2024, according to Technavio
- 05/07/2020
|
Was The Smart Money Right About Amneal Pharmaceuticals, Inc. (AMRX)?
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P; 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 05/06/2020
|
Patent Filings Roundup: Blackberry Accused of Abuse, PayPal Isn’t Playing, WSOU Earns Its Frequent Filer Card
- This week in patent filings, PTAB filings are back up, with four post grant reviews and 37 inter partes reviews, while there were 83 district court complaints; the district court numbers skew high because of the WSOU entities’ proclivity for filing dozens of independent complaints per defendant, as discussed below.
- 05/06/2020
|
Huge boost for Covid-19 vaccine with test monkeys infection-free four weeks on
- 'Millions' of doses of Oxford University's vaccine could be available as early as September with human trials, consisting of 6,000 participants, set to begin in May, it has been reported
- 04/28/2020
|
SVB Leerink Equities Analysts Increase Earnings Estimates for Amneal Pharmaceuticals Inc (NYSE:AMRX)
- Amneal Pharmaceuticals Inc (NYSE:AMRX) – Stock analysts at SVB Leerink upped their FY2021 earnings per share (EPS) estimates for Amneal Pharmaceuticals in a research note issued on Thursday, April 23rd. SVB Leerink analyst A. Fadia now anticipates that the company will post earnings per share of $0.67 for the year, up from their prior forecast […]
- 04/27/2020
|
Amneal to Report First Quarter 2020 Results on May 11, 2020
- Amneal to Report First Quarter 2020 Results on May 11, 2020
- 04/24/2020
|
FACTBOX-Global pharma industry steps up efforts to battle coronavirus
- Drugmakers across the globe are rushing to develop a treatment or vaccine for the fast-spreading coronavirus that has wreaked havoc across the globe,
killing over 191,000 people and ravaging financial markets.
Along with medical researchers and public health authorities, diagnostic test makers are also launching their own test kits to expand testing.
Experts have warned vaccines could take 12-18 months to develop, and trials for treatments are still in early stages of development.
DIAGNOSTICS
Date of Company Progress Story link
last
update
March 31 Qiagen NV The German company has launched a test in Europe that may detect coronavirus in about
an hour. The test is also allowed for use in the United States.
April 15 Abbott Laboratories Has launched three separate tests for the coronavirus, including an antibody test.
March 21 Danaher Corp Company's Cepheid unit has gained U.S. approval for a rapid diagnostic test that can
detect the coronavirus in about 45 minutes.
April 17 Roche Holding AG The U.S. has authorized a test made by the Swiss pharma company that can provide
results in 3-1/2 hours and can produce up to 4,128 results daily. It is also working
to make an antibody test available by May.
April 20 Co-Diagnostics Has received emergency authorization for its test in the United States and has shipped
the kits to a dozen states and received orders from nearly 50 countries.
March 23 Laboratory Corp of America Holdings Its coronavirus tests are available for ordering by healthcare providers. It is to be
used in patients who meet the current guidance for testing.
March 5 Quest Diagnostics Inc Laboratory company has already rolled out a test service for the coronavirus.
March 16 Hologic Inc Emergency use of its diagnostic kit, which is able to process up to 1,000 tests in 24
hours, is permitted in United States.
March 17 OPKO Health Company's diagnostics unit has tied up with the New York State Department of Health to
provide drive-through facility on the East Coast to test COVID-19 and expects to begin
offering up to 5,000 tests a day at additional satellite testing sites.
March 27 Sugentech Inc The South Korean company has started selling a blood test outside the United States.
March 25 Biomerica Inc Has received orders for its blood test from Europe and Middle East.
March 24 PerkinElmer Inc Emergency use of its coronavirus test allowed in the United States, and the device is
available in over 30 countries worldwide.
VACCINES
Date of Company name Progress Story link
last
update
April 16 Moderna Inc A patient was dosed with the company's vaccine on March 16 in an early-stage trial.
Received a $483 million funding from a U.S> government agency to speed up the vaccine's
development.
April 14 GlaxoSmithKline Plc The company and Sanofi SA said they would develop a vaccine for the
coronavirus and expect to start clinical trials in the second half of 2020.
April 9 BioNTech SE The German drugmaker is working with Pfizer Inc to develop millions of vaccines
by the end of 2020. The companies plan to start trials of the vaccine as early as this
month.
April 6 Inovio Pharma The U.S.-based drug developer has begun a trial of its vaccine. It plans to have one
million doses available by the end of 2020 for trials and emergency use.
March 30 Johnson & Johnson Signed a $1 billion deal with the U.S. to create more than 1 billion doses of a
vaccine. The pharma giant plans to test the vaccine in humans by September.
TREATMENTS
Date of Company name Progress Story link
last
update
April 23 AstraZeneca Company is testing a diabetes drug, Farxiga, as a potential treatment for COVID-19 patients who also had
existing heart and kidney problems.
April 20 Novartis AG Has reached an agreement with U.S. regulators to hold a randomized trial of generic malaria drug
hydroxychloroquine against COVID-19 disease in 440 hospitalised patients.
April 23 Gilead Sciences Inc Company's experimental antiviral drug, remdesivir, failed to help patients with severe COVID-19 in a
clinical trial conducted in China, but the drugmaker said the findings were inconclusive because the study
was terminated early.
March 30 Has expanded the testing of its rheumatoid arthritis drug, Kevzara, with partner Sanofi .
Regeneron Pharmaceuticals Inc Regeneron has also identified hundreds of antibodies that could treat or prevent the coronavirus and was
preparing to begin clinical trials by early summer.
March 23 China approved the use of the company's anti-inflammation drug Actemra in patients who develop severe
Roche complications from the coronavirus. Has received U.S. clearance to test the drug in coronavirus, but the
company has not disclosed when it expects to start U.S. trials.
March 5 BioCryst Pharmaceuticals Inc Its treatment, galidesivir, works by interfering with a virus' ability to replicate. The antiviral has
shown promise in a range of viruses and proven to be safe in healthy volunteers.
March 12 Eli Lilly Co The U.S.
- 04/24/2020
|
FDA cautions on use of malaria drugs for COVID-19 outside of hospitals
- In a statement, the FDA is cautioning against the use of malaria meds chloroquine and hydroxychloroquine outside of the hospital setting for the treatment of COVID-19 due to the risk of adverse heart
- 04/24/2020
|
Finnish drugmaker Orion raises profit view as coronavirus lifts demand
- Finnish drugmaker Orion raised its 2020 operating profit forecast on Friday, helped by strong demand for drugs including a sedative and a respiratory treatment due to coronavirus pandemic.
- 04/24/2020
|
UPDATE 1-Finnish drugmaker Orion raises profit view as coronavirus lifts demand
- Finnish drugmaker Orion raised its 2020 operating profit forecast on Friday, helped by strong demand for drugs including a sedative and a respiratory treatment due to coronavirus pandemic.
- 04/24/2020
|
Royal Bank of Canada Reiterates Hold Rating for Amneal Pharmaceuticals (NYSE:AMRX)
- Royal Bank of Canada reaffirmed their hold rating on shares of Amneal Pharmaceuticals (NYSE:AMRX) in a research note released on Thursday morning, AnalystRatings.com reports. They currently have a $4.00 price objective on the stock. AMRX has been the subject of several other reports. Morgan Stanley cut their price objective on Amneal Pharmaceuticals from $5.00 to […]
- 04/20/2020
|
Ladenburg Thalmann Financial Services Inc. Sells 7,373 Shares of Amneal Pharmaceuticals Inc (NYSE:AMRX)
- Ladenburg Thalmann Financial Services Inc. lowered its stake in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 17.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 36,094 shares of the company’s stock after selling 7,373 shares during the quarter. Ladenburg Thalmann Financial Services Inc.’s holdings in Amneal Pharmaceuticals were worth $178,000 as of its […]
- 04/19/2020
|
Cubist Systematic Strategies LLC Sells 40,394 Shares of Amneal Pharmaceuticals Inc (NYSE:AMRX)
- Cubist Systematic Strategies LLC lessened its holdings in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 62.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 24,004 shares of the company’s stock after selling 40,394 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in […]
- 04/19/2020
|
Amneal Pharmaceuticals Inc (NYSE:AMRX) Shares Bought by Alliancebernstein L.P.
- Alliancebernstein L.P. raised its holdings in Amneal Pharmaceuticals Inc (NYSE:AMRX) by 3.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 233,249 shares of the company’s stock after acquiring an additional 7,600 shares during the period. Alliancebernstein L.P. owned 0.08% of Amneal Pharmaceuticals worth $1,124,000 at the […]
- 04/18/2020
|
Research Analysts Issue Forecasts for Amneal Pharmaceuticals Inc's FY2020 Earnings (NYSE:AMRX)
- Amneal Pharmaceuticals Inc (NYSE:AMRX) – Equities research analysts at Piper Sandler cut their FY2020 earnings per share (EPS) estimates for Amneal Pharmaceuticals in a research report issued to clients and investors on Tuesday, April 14th. Piper Sandler analyst D. Amsellem now forecasts that the company will earn $0.35 per share for the year, down from […]
- 04/18/2020
|
Q1 2020 EPS Estimates for Amneal Pharmaceuticals Inc Decreased by Piper Sandler (NYSE:AMRX)
- Amneal Pharmaceuticals Inc (NYSE:AMRX) – Piper Sandler dropped their Q1 2020 earnings per share (EPS) estimates for Amneal Pharmaceuticals in a note issued to investors on Tuesday, April 14th. Piper Sandler analyst D. Amsellem now forecasts that the company will post earnings of $0.08 per share for the quarter, down from their prior forecast of […]
- 04/18/2020
|
Amneal Pharmaceuticals Inc (NYSE:AMRX) Short Interest Up 17.6% in March
- Amneal Pharmaceuticals Inc (NYSE:AMRX) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 6,230,000 shares, an increase of 17.6% from the March 15th total of 5,296,700 shares. Currently, 6.6% of the company’s stock are sold short. Based on an average […]
- 04/17/2020
|
RBC Capital Maintains a Hold Rating on Amneal Pharmaceuticals (AMRX)
- In a report released yesterday,
Randall Stanicky
from RBC Capital maintained a
Hold
rating on Amneal Pharmaceuticals (
AMRX
–
Research Report
), with a price target of
$4.00
. The company’s shares closed last Thursday at $3.37, close to its 52-week l
- 04/16/2020
|
Eagle Pharma's Ryanodex shows in vitro antiviral activity against COVID-19 EGRX;AMRX
- Eagle Pharma's Ryanodex shows in vitro antiviral activity against COVID-19 EGRX AMRX
- 04/16/2020
|
BRIEF-Amneal Launches Generic Butrans Following ANDA Approval By FDA
- Amneal Pharmaceuticals Inc:
- 04/16/2020
|
Amneal Launches Generic Butrans Following ANDA Approval by FDA
- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Butrans® (buprenorphine) Transdermal System, 5 mcg/
- 04/16/2020
|
Eagle Pharmaceuticals Announces Laboratory Test Results Demonstrating In Vitro Antiviral Activity of RYANODEX (dantrolene sodium) Against Coronavirus SARS-CoV-2
- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle"), a New Jersey-based pharmaceutical company, today announced that its product RYANODEX® (dantrolene sodium) for injectable suspension inhibited the growth of SARS-CoV-2, the virus causing the COVID-19 pandemic, in a controlled in vitro laboratory
- 04/16/2020
|
Bank of America Corp DE Increases Position in Amneal Pharmaceuticals Inc (NYSE:AMRX)
- Bank of America Corp DE raised its holdings in Amneal Pharmaceuticals Inc (NYSE:AMRX) by 205.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 721,720 shares of the company’s stock after purchasing an additional 485,692 shares during the quarter. Bank of America Corp […]
- 04/16/2020
|
Amneal Pharmaceuticals Moving to a Virtual Meeting Format for 2020 Annual Meeting of Stockholders
- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced that its 2020 Annual Meeting of Stockholders (the "Annual Meeting") will be a virtual meeting instead of an in-person meeting. This change is in response to the ongoing COVID-19 pandemic and is intended to protect the health and safety of Amneal’s stockholders and employees.
- 04/15/2020
|
Bank of New York Mellon Corp Has $6.37 Million Holdings in Amneal Pharmaceuticals Inc (NYSE:AMRX)
- Bank of New York Mellon Corp lifted its stake in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 147.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,322,416 shares of the company’s stock after buying an additional 787,166 shares during the period. Bank of New […]
- 04/15/2020
|
Amneal running out of hydroxychloroquine raw material, co-CEOs say
- Amneal Pharmaceuticals (NYSE:AMRX) may soon run out of the raw ingredients to make hydroxychloroquine because Finland is keeping the drug for domestic use, the company's co-CEOs tell Reuters.Amneal ha
- 04/12/2020
|
Did You Manage To Avoid Amneal Pharmaceuticals’s (NYSE:AMRX) Devastating 75% Share Price Drop?
- Amneal Pharmaceuticals, Inc. (NYSE:AMRX) shareholders should be happy to see the share price up 16% in the last month...
- 04/11/2020
|
EXCLUSIVE-Amneal running out of hydroxychloroquine raw material due to Finnish restrictions
- Amneal Pharmaceuticals could soon run out of the raw ingredients to make more of the antimalarial drug hydroxychloroquine that has been touted as a potential treatment for COVID-19 because Finland is keeping the drug for domestic use, according to the generic drugmaker's chief executives.
- 04/10/2020
|
Exclusive: Amneal running out of hydroxychloroquine raw material due to Finnish restrictions
- Amneal Pharmaceuticals could soon run out of the raw ingredients to make more of the antimalarial drug hydroxychloroquine that has been touted as a potential treatment for COVID-19 because Finland is keeping the drug for domestic use, according to the generic drugmaker's chief executives. Amneal has committed to producing about 20 million hydroxychloroquine tablets by mid-April, but will face challenges making any more after that because of difficulties acquiring active pharmaceutical ingredients from its supplier in Finland, co-CEOs Chirag and Chintu Patel said in an interview. "As the demand has increased all across the globe... the Finnish government has put out an emergency order to prioritize their domestic use for local needs," co-CEO Chintu Patel said in an interview on Tuesday.
- 04/10/2020
|
EXCLUSIVE-Amneal running out of hydroxychloroquine raw material due to Finnish restrictions
- Amneal Pharmaceuticals could soon run out of the raw ingredients to make more of the antimalarial drug hydroxychloroquine that has been touted as a potential treatment for COVID-19 because Finland is keeping the drug for domestic use, according to the generic drugmaker's chief executives.
- 04/10/2020
|
Amneal Pharmaceuticals (NYSE:AMRX) Shares Down 7.3%
- Shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) dropped 7.3% during trading on Tuesday . The company traded as low as $2.86 and last traded at $2.91, approximately 2,324,233 shares traded hands during mid-day trading. An increase of 23% from the average daily volume of 1,892,446 shares. The stock had previously closed at $3.14. AMRX has been […]
- 04/08/2020
|
Amneal Pharmaceuticals Inc (NYSE:AMRX) Given Consensus Recommendation of "Hold" by Brokerages
- Amneal Pharmaceuticals Inc (NYSE:AMRX) has been assigned an average recommendation of “Hold” from the fourteen analysts that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price […]
- 04/08/2020
|
Trump and his allies have a stake in promoting hydroxychloroquine
- Several pharmaceutical companies stand to profit from the drug's promotion, including shareholders and senior executives with connections to the president.
- 04/07/2020
|
Barron's on MarketWatch: Could COVID-19 bring generic-drug making back to U.S.?
- SVB Leerink analyst Ami Fadia says the pandemic could bring some relief to beaten-down generic-drug companies.
- 04/07/2020
|
Covid-19 Could Bring Generic Drug Manufacturing Back to the U.S., Analyst Writes
- SVB Leerink analyst Ami Fadia says the pandemic could bring some relief to beaten-down generic-drug companies.
- 04/07/2020
|
Trump’s personal stake in the malaria-drug maker Sanofi could be as small as $99
- The New York Times, in a major article, says Trump has a “small personal stake” in Sanofi, the French drugmaker that produces the drug. Here’s how small.
- 04/07/2020
|
Amneal Pharmaceuticals (NYSE:AMRX) Trading 9.4% Higher
- Amneal Pharmaceuticals Inc (NYSE:AMRX) traded up 9.4% on Monday . The company traded as high as $3.16 and last traded at $3.14, 1,525,343 shares traded hands during trading. A decline of 19% from the average session volume of 1,885,937 shares. The stock had previously closed at $2.87. A number of equities research analysts have weighed […]
- 04/07/2020
|
Malaria drugs in high demand amid COVID-19
- States across the U.S. are instituting measures to prevent hoarding of malaria drugs hydroxychloroquine and chloroquine in an effort to maintain supply amid acute demand from pharmacies and COVID-19 p
- 04/05/2020
|
Great West Life Assurance Co. Can Purchases New Holdings in Amneal Pharmaceuticals Inc (NYSE:AMRX)
- Great West Life Assurance Co. Can purchased a new stake in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) in the 4th quarter, Holdings Channel reports. The fund purchased 7,150 shares of the company’s stock, valued at approximately $34,000. Several other institutional investors and hedge funds have also added to or reduced their stakes in AMRX. California […]
- 04/03/2020
|
Amneal Pharmaceuticals Inc (NYSE:AMRX) Stock Position Raised by Amalgamated Bank
- Amalgamated Bank lifted its position in Amneal Pharmaceuticals Inc (NYSE:AMRX) by 19.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,134 shares of the company’s stock after acquiring an additional 3,324 shares during the period. Amalgamated Bank’s holdings in […]
- 04/03/2020
|
$439.11 Million in Sales Expected for Amneal Pharmaceuticals Inc (NYSE:AMRX) This Quarter
- Equities research analysts forecast that Amneal Pharmaceuticals Inc (NYSE:AMRX) will announce $439.11 million in sales for the current quarter, according to Zacks. Five analysts have issued estimates for Amneal Pharmaceuticals’ earnings. The lowest sales estimate is $429.80 million and the highest is $450.30 million. Amneal Pharmaceuticals reported sales of $446.12 million in the same quarter […]
- 04/03/2020
|
FDA: You Can Use Chloroquine to Treat COVID-19; EU Regulators: Not Just Yet
- Regulators take different approaches to the unapproved medications.
- 04/02/2020
|
Amneal Pharmaceuticals (AMRX) Gets a Hold Rating from Morgan Stanley
- In a report released today,
David Risinger
from Morgan Stanley maintained a
Hold
rating on Amneal Pharmaceuticals (
AMRX
–
Research Report
), with a price target of
$3.00
. The company’s shares closed last Thursday at $3.01, close to its 52-week low
- 04/02/2020
|
Ranitidine products to be removed from U.S. market - FDA
- The FDA is requesting all manufacturers of ranitidine drugs to withdraw them immediately from the U.S. market due to the presence of an impurity called N-Nitrosodimethylamine (NDMA), a suspect
- 04/01/2020
|
UBS unconvinced with efficacy of malaria drug for COVID-19
- In a note, UBS regards the republished results from one of the first randomized trials evaluating malaria drug hydroxychloroquine (HCQ) in COVID-19 patients as "inconclusive."62 patien
- 04/01/2020
|
Analysts Have Conflicting Sentiments on These Healthcare Companies: Danaher (DHR), Amneal Pharmaceuticals (AMRX) and CytomX Therapeutics (CTMX)
- Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Danaher (DHR), Amneal Pharmaceuticals (AMRX) and CytomX
- 04/01/2020
|
ABT, DD among premarket gainers
- Plus Therapeutics. (NASDAQ:PSTV) +63% in-licenses novel oncology candidates.Bellerophon Therapeutics (NASDAQ:BLPH) +40% as first COVID-19 patient has been treated with the INOpulse inhaled nitric oxid
- 03/30/2020
|
Don't Chase The Sugar High
- The short- and long-term outlook is good, but mid-term risks are high. Here's what you can do now. Top sectors and stocks you ought to be considering for portfo
- 03/27/2020
|
Blueshift Asset Management LLC Has $321,000 Position in Amneal Pharmaceuticals Inc (NYSE:AMRX)
- Blueshift Asset Management LLC raised its holdings in Amneal Pharmaceuticals Inc (NYSE:AMRX) by 35.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 66,564 shares of the company’s stock after purchasing an additional 17,294 shares during the period. Blueshift Asset Management LLC’s holdings in Amneal Pharmaceuticals were worth $321,000 at the end of the […]
- 03/27/2020
|
State of Texas and Senator Bryan Hughes Secure a Donation of Hydroxychloroquine Sulfate from Amneal Pharmaceuticals for Texas Patients
- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company"), one of the largest U.S.-based generics manufacturers, and the State of Texas today announced that they are responding to the national COVID-19 health emergency. Amneal has donated 1,000,000 hydroxychloroquine sulfate tablets to the Texas State Pharmacy, which will be directly distributed to hospitals for potential use in treating COVID-19 patients.
- 03/26/2020
|
India clamps down on export of malaria drug for Covid-19
- In a note, UBS reports that India's Directorate General of Foreign Trade has instituted a moratorium on the export of hydroxychloroquine, a malaria drug in high demand for the treatment of severely il
- 03/26/2020
|
Top Drug Stocks Under $5
- Healthcare bargain hunters can find good values in quality low-priced stocks.
- 03/26/2020
|
Benzinga Pro's Stock To Watch For Wed., Mar. 25, 2020: AMRX
- Benzinga Pro's Stocks To Watch For Wednesday * Amneal Pharmaceuticals (AMRX) \- Shares of this pharma and therapeutics maker rallied about 50% over the last five trading sessions as traders viewed the stock as a play on a controversial potential coronavirus treatment, hydroxychloroquine. Approved by the FDA for usage by patients treating malaria and lupus, President Trump has repeatedly touted the drug as a treatment for the coronavirus infection, COVID-19. But earlier clinical data on how effective hydroxychloroquine and its root chloroquine are in treating coronavirus has not been promising. In a recent study of 30 patients by a Chinese university, 13 of 15 who were given the drug as a treatment showed they didn't have the disease after a week of usage. For the remaining 15 patients in the study who did not receive the treatment, 14 no longer showed they had the disease. In addition, recent reports have suggested people may be misusing the drug without proper physician guidance in an attempt to try to prevent the coronavirus infection. The uncertainty about the drug as a potential treatment hasn't stopped companies like Amneal, Teva Pharmaceutical (TEVA) and Roche (RHHBY) from accelerating distribution and production and donating supplies to health officials. See more from Benzinga * Benzinga Pro's Stock To Watch For Fri., Mar. 20, 2020: TEVA(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 03/25/2020
|
Chloroquine, Hydroxychloroquine And Coronavirus: What You Should Know
- One of the difficulties facing American investors during the COVID-19 outbreak is separating fact from fiction, rumor from truth and speculation from confirmation.
President...
- 03/24/2020
|
Companies Plan to Boost Production of Controversial Malaria Drug as Demand Jumps
- Demand for hydroxychloroquine, the malaria drug that President Trump has touted as a treatment for Covid-19 despite limited evidence, has already begun to increase, according to a note from SVB Leerink analyst Ami Fadia.
- 03/24/2020
|
Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals (AMRX) Stock?
- Investors need to pay close attention to Amneal Pharmaceuticals (AMRX) stock based on the movements in the options market lately.
- 03/24/2020
|
Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals (AMRX) Stock?
- Investors need to pay close attention to Amneal Pharmaceuticals (AMRX) stock based on the movements in the options market lately.
- 03/24/2020
|
Amneal (AMRX) Catches Eye: Stock Jumps 6.7%
- Amneal (AMRX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- 03/24/2020
|
Amneal (AMRX) Catches Eye: Stock Jumps 6.7%
- Amneal (AMRX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- 03/24/2020
|
FACTBOX-Global pharma industry intensifies efforts to battle coronavirus
- Drugmakers across the globe are rushing to develop a treatment or vaccine for th...
- 03/23/2020
|
BMY, TLRY among premarket gainers
- Waitr Holdings (NASDAQ:WTRH) +51% on expanding into Grocery Delivery.Innate Pharma S.A. (NASDAQ:IPHA) +34% on potential use of cancer drug for Covid-19.DCP Midstream, LP (NYSE:DCP) +31% on cutting 202
- 03/23/2020
|
Trump goes all-in on anti-malarial treatment
- The president yesterday took plenty of heat from the usual suspects for conveying a bit of optimism over an anti-malarial drug that - according to some reports (here's one) - has had great success in
- 03/21/2020
|
Paul M. Meister Purchases 353,649 Shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) Stock
- Amneal Pharmaceuticals Inc (NYSE:AMRX) Director Paul M. Meister bought 353,649 shares of the company’s stock in a transaction on Wednesday, March 18th. The stock was bought at an average cost of $3.19 per share, with a total value of $1,128,140.31. Following the completion of the acquisition, the director now owns 149,439 shares of the company’s […]
- 03/21/2020
|
Amneal Ramping Up Malaria Drug Production to Treat Coronavirus Patients
- The company expects to produce around 20 million tablets within a month.
- 03/21/2020
|
Are Chloroquine and Hydrochloroquine Approved to Treat COVID-19?
- No, but doctors can still use the drugs despite limited evidence of their effectiveness.
- 03/21/2020
|
BRIEF-Amneal Accelerates Production Of Hydroxychloroquine Sulfate
- Amneal Pharmaceuticals Inc:
- 03/20/2020
|
Amneal Accelerates Distribution and Production of Hydroxychloroquine Sulfate to Meet Potential Needs of COVID-19 Patients Nationwide
- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company"), one of the largest U.S.-based generics manufacturers, today announced that it is responding to the national COVID-19 health emergency by building on its existing supply of hydroxychloroquine sulfate.
- 03/20/2020
|
Biotech and hospitality stocks among premarket gainers
- Bellerophon Therapeutics (NASDAQ:BLPH) +472% on FDA nod for emergency use of INOpulse for Covid-19.Rand Capital (NASDAQ:RAND) +87% on its portfolio company developing automated test kits for detection
- 03/20/2020
|
Should Value Investors Consider Amneal Pharmaceuticals, Inc.(AMRX), RadNet, Inc.(RDNT) | Post Analyst
- Amneal Pharmaceuticals, Inc. (AMRX) is now among the bigger bargains in its industry. Within the last year the price ranged from $2.27 – 14.65 and there is a wide opportunity to get in. Its next earnings report will be released on May 14, 2020. RadNet, Inc.(RDNT) move, based on 2 analysts offering 12 month price …
- 03/20/2020
|
Mylan ramps up U.S. production of malaria drug for Covid-19 use
- Mylan N.V. (MYL +6%) has restarted production of hydroxychloroquine sulfate tablets at its West Virginia facility in order to meet COVID-19-related demand, although it is not formerly approved for thi
- 03/19/2020
|
Prudential Financial Inc. Has $4.41 Million Holdings in Amneal Pharmaceuticals Inc (NYSE:AMRX)
- Prudential Financial Inc. lessened its holdings in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 0.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 915,880 shares of the company’s stock after selling 4,708 shares during the quarter. Prudential Financial Inc. owned 0.31% of Amneal Pharmaceuticals […]
- 03/17/2020
|
Amneal Pharmaceuticals Inc (NYSE:AMRX) Given Consensus Rating of "Hold" by Brokerages
- Amneal Pharmaceuticals Inc (NYSE:AMRX) has received an average recommendation of “Hold” from the thirteen analysts that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company. The average 1 year price target […]
- 03/14/2020
|
Chintu Patel Buys 100,000 Shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) Stock
- Amneal Pharmaceuticals Inc (NYSE:AMRX) CEO Chintu Patel acquired 100,000 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were bought at an average price of $3.09 per share, for a total transaction of $309,000.00. Following the acquisition, the chief executive officer now owns 356,107 shares of the company’s stock, valued […]
- 03/13/2020
|
Insider Buying: Amneal Pharmaceuticals Inc (NYSE:AMRX) Director Acquires 32,111 Shares of Stock
- Amneal Pharmaceuticals Inc (NYSE:AMRX) Director Gautam Patel bought 32,111 shares of Amneal Pharmaceuticals stock in a transaction on Monday, March 2nd. The stock was acquired at an average cost of $3.88 per share, for a total transaction of $124,590.68. Following the acquisition, the director now owns 38,218 shares in the company, valued at approximately $148,285.84. […]
- 03/12/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) * Bicycle Therapeutics PLC (NASDAQ: BCYC) (reacted to its fourth-quarter results) * Centogene NV (NASDAQ: CNTG) * Tiziana Life Sciences PLC (NASDAQ
- 03/12/2020
|
Chirag K. Patel Purchases 34,641 Shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) Stock
- Amneal Pharmaceuticals Inc (NYSE:AMRX) CEO Chirag K. Patel bought 34,641 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was purchased at an average cost of $3.87 per share, with a total value of $134,060.67. Following the completion of the transaction, the chief executive officer now owns 40,748 shares in […]
- 03/12/2020
|
BRIEF-Amneal Pharmaceuticals Appoints Tasos Konidaris As Senior Vice President, CFO
- Amneal Pharmaceuticals Inc:
- 03/11/2020
|
Amneal Pharmaceuticals Appoints Tasos Konidaris as Senior Vice President, Chief Financial Officer
- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced it has appointed Tasos Konidaris as Senior Vice President, Chief Financial Officer, effective March 12, 2020. Mr. Konidaris succeeds Todd Branning, who is no longer serving in this role, but remains available to the Company through March 31, 2020.
- 03/11/2020
|
Insider Buying: Amneal Pharmaceuticals Inc (NYSE:AMRX) CEO Purchases 58,938 Shares of Stock
- Amneal Pharmaceuticals Inc (NYSE:AMRX) CEO Chirag K. Patel bought 58,938 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, March 4th. The shares were bought at an average cost of $3.97 per share, with a total value of $233,983.86. Following the completion of the acquisition, the chief executive officer now owns 40,748 shares of […]
- 03/11/2020
|
Analysts Expect Amneal Pharmaceuticals Inc (NYSE:AMRX) Will Post Quarterly Sales of $435.77 Million
- Brokerages predict that Amneal Pharmaceuticals Inc (NYSE:AMRX) will post $435.77 million in sales for the current quarter, according to Zacks. Five analysts have provided estimates for Amneal Pharmaceuticals’ earnings. The lowest sales estimate is $429.80 million and the highest is $449.90 million. Amneal Pharmaceuticals reported sales of $446.12 million during the same quarter last year, […]
- 03/10/2020
|
Rhumbline Advisers Acquires 16,872 Shares of Amneal Pharmaceuticals Inc (NYSE:AMRX)
- Rhumbline Advisers lifted its holdings in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 13.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 147,019 shares of the company’s stock after purchasing an additional 16,872 shares during the quarter. Rhumbline Advisers’ holdings in Amneal Pharmaceuticals were worth $709,000 at the end of the most recent […]
- 03/08/2020
|
New York State Common Retirement Fund Grows Stock Holdings in Amneal Pharmaceuticals Inc (NYSE:AMRX)
- New York State Common Retirement Fund grew its position in Amneal Pharmaceuticals Inc (NYSE:AMRX) by 24.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 106,200 shares of the company’s stock after buying an additional 20,900 shares during the quarter. New York […]
- 03/08/2020
|
Joseph Todisco of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Just Spent US$145k On Shares
- Investors who take an interest in Amneal Pharmaceuticals, Inc. (NYSE:AMRX) should definitely note that insider Joseph...
- 03/07/2020
|
Amneal Pharmaceuticals (NYSE:AMRX) Upgraded by Zacks Investment Research to Hold
- Zacks Investment Research upgraded shares of Amneal Pharmaceuticals (NYSE:AMRX) from a strong sell rating to a hold rating in a research note published on Tuesday morning, Zacks.com reports. According to Zacks, “Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates […]
- 03/07/2020
|
Amneal Pharmaceuticals (NYSE:AMRX) Trading 7.1% Higher Following Insider Buying Activity
- Amneal Pharmaceuticals Inc (NYSE:AMRX)’s stock price traded up 7.1% on Wednesday after an insider bought additional shares in the company. The stock traded as high as $4.17 and last traded at $4.09, 2,246,252 shares changed hands during trading. An increase of 52% from the average session volume of 1,480,245 shares. The stock had previously closed […]
- 03/06/2020
|
Amneal Pharmaceuticals Inc (NYSE:AMRX) SVP Joseph Todisco Buys 40,000 Shares
- Amneal Pharmaceuticals Inc (NYSE:AMRX) SVP Joseph Todisco acquired 40,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Friday, February 28th. The stock was purchased at an average cost of $3.62 per share, for a total transaction of $144,800.00. Following the completion of the transaction, the senior vice president now directly owns 246,845 […]
- 03/05/2020
|
Amneal Pharmaceuticals (NYSE:AMRX) Shares Up 7.1% After Insider Buying Activity
- Amneal Pharmaceuticals Inc (NYSE:AMRX) shot up 7.1% during trading on Wednesday after an insider bought additional shares in the company. The company traded as high as $4.17 and last traded at $4.09, 2,246,252 shares were traded during mid-day trading. An increase of 52% from the average session volume of 1,480,245 shares. The stock had previously […]
- 03/05/2020
|
Valisure Challenges FDA's Claims on Metformin's Safety
- The online pharmacy conducted its own tests of the type-2 diabetes drug and found excessive levels of a carcinogenic compound in 42% of the batches it tested.
- 03/03/2020
|
Online pharmacy Valisure says tests show carcinogen in diabetes drug metformin
- Online pharmacy Valisure said on Monday its tests showed high levels of a probab...
- 03/02/2020
|
SunTrust Banks Cuts Amneal Pharmaceuticals (NYSE:AMRX) Price Target to $5.00
- Amneal Pharmaceuticals (NYSE:AMRX) had its price target reduced by SunTrust Banks from $6.00 to $5.00 in a research report released on Thursday morning, BenzingaRatingsTable reports. SunTrust Banks currently has a buy rating on the stock. A number of other analysts have also issued reports on AMRX. BTIG Research lifted their price target on shares of […]
- 03/02/2020
|
SunTrust Banks Analysts Lower Earnings Estimates for Amneal Pharmaceuticals Inc (NYSE:AMRX)
- Amneal Pharmaceuticals Inc (NYSE:AMRX) – SunTrust Banks decreased their Q2 2020 EPS estimates for shares of Amneal Pharmaceuticals in a research note issued to investors on Wednesday, February 26th. SunTrust Banks analyst G. Gilbert now expects that the company will post earnings per share of $0.11 for the quarter, down from their previous estimate of […]
- 03/02/2020
|
Q1 2020 Earnings Estimate for Amneal Pharmaceuticals Inc (NYSE:AMRX) Issued By Piper Sandler
- Amneal Pharmaceuticals Inc (NYSE:AMRX) – Piper Sandler cut their Q1 2020 earnings per share (EPS) estimates for shares of Amneal Pharmaceuticals in a report issued on Wednesday, February 26th. Piper Sandler analyst D. Amsellem now forecasts that the company will post earnings of $0.10 per share for the quarter, down from their prior estimate of […]
- 03/02/2020
|
American International Group Inc. Has $357,000 Holdings in Amneal Pharmaceuticals Inc (NYSE:AMRX)
- American International Group Inc. boosted its holdings in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 25.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 74,031 shares of the company’s stock after buying an additional 14,867 shares during the quarter. […]
- 03/01/2020
|
Amneal Pharmaceuticals (NYSE:AMRX) Rating Lowered to Hold at ValuEngine
- Amneal Pharmaceuticals (NYSE:AMRX) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, ValuEngine reports. Several other research firms have also recently weighed in on AMRX. Royal Bank of Canada lifted their price objective on Amneal Pharmaceuticals from $3.00 to $4.00 […]
- 02/28/2020
|
Amneal Pharmaceuticals Inc (NYSE:AMRX) Short Interest Update
- Amneal Pharmaceuticals Inc (NYSE:AMRX) was the target of a large drop in short interest during the month of February. As of February 14th, there was short interest totalling 3,940,000 shares, a drop of 27.3% from the January 30th total of 5,420,000 shares. Currently, 4.8% of the shares of the company are sold short. Based on […]
- 02/28/2020
|
Amneal Pharmaceuticals Inc (NYSE:AMRX) Shares Acquired by California Public Employees Retirement System
- California Public Employees Retirement System grew its stake in Amneal Pharmaceuticals Inc (NYSE:AMRX) by 66.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 196,449 shares of the company’s stock after acquiring an additional 78,178 shares during the period. California Public Employees Retirement System owned about 0.07% […]
- 02/27/2020
|
